Abstract: A mooring line connector assembly (1) and a corresponding tensioner (28) are described. The mooring line connector assembly (1) comprises complementary male (2) and female (3) connectors, wherein the male connector (2) is rigid and the female connector (3) is connectable to the male connector (2) at a plurality of points along its length, so as to vary the tension applied to the mooring line. Locking balls engageable with grooves disposed along the length of the male connector (2) can allow the female connector to connect at different points along the male connector. A tensioner (28) allows the tension to be adjusted. The tensioner includes a first part (29) arranged to engage with the male connector (2) and a second part (29) arranged to engage with the female connector (3). The first part (29) reciprocates relative to the second part so as to move the male connector (2) relative to the female connector and thereby change the point at which the female connector is connected to the male connector.

Abstract: A mooring line connector assembly (1) and a corresponding tensioner (28) are described. The mooring line connector assembly (1) comprises complementary male (2) and female (3) connectors, wherein the male connector (2) is rigid and the female connector (3) is connectable to the male connector (2) at a plurality of points along its length, so as to vary the tension applied to the mooring line. Locking balls engageable with grooves disposed along the length of the male connector (2) can allow the female connector to connect at different points along the male connector. A tensioner (28) allows the tension to be adjusted. The tensioner includes a first part (29) arranged to engage with the male connector (2) and a second part (29) arranged to engage with the female connector (3). The first part (29) reciprocates relative to the second part so as to move the male connector (2) relative to the female connector and thereby change the point at which the female connector is connected to the male connector.

Abstract: A mooring connector assembly (3) has a body (10) arranged to be pivotally mounted to a structure (1), such as a tethered buoy, to be moored for movement about a pivot axis. At least a part of the body extends below the pivot axis when so mounted and oriented for use. A line stopper (17) is mounted to the part of the body which extends below the pivot axis in use and is operative to retain a mooring line (2) relative to the body. The body is configured to receive a tensioner (20) for tensioning a mooring line (2) retained by the stopper such that the tensioner urges the line at a point which is below the pivot axis when the body is oriented for use. The body may be an elongate tube (10) pivotally connected to a structure to be moored (1) at one end and fitting with a chain stopper (17) at the opposite end. The tube is configured to receive a chain tensioner (20) between the chain stopper (17) and pivot axis.

Abstract: A mooring connector assembly (3) has a body (10) arranged to be pivotally mounted to a structure (1), such as a tethered buoy, to be moored for movement about a pivot axis. At least a part of the body extends below the pivot axis when so mounted and oriented for use. A line stopper (17) is mounted to the part of the body which extends below the pivot axis in use and is operative to retain a mooring line (2) relative to the body. The body is configured to receive a tensioner (20) for tensioning a mooring line (2) retained by the stopper such that the tensioner urges the line at a point which is below the pivot axis when the body is oriented for use. The body may be an elongate tube (10) pivotally connected to a structure to be moored (1) at one end and fitting with a chain stopper (17) at the opposite end. The tube is configured to receive a chain tensioner (20) between the chain stopper (17) and pivot axis.

Abstract: The invention provides assays, methods, systems, compositions, and kits for diagnosing and treating cancer.

Abstract: The invention provides assays, methods, systems, compositions, and kits for diagnosing and treating cancer.

Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Abstract: This invention provides an extensible method for performing management operations on known and unknown targets. The extensible method is implemented on a fully extensible system where management software and triggers that cause these management operations to be run are easily extended in the field. The triggers may include information indicating a change in inventory, product state, or an event, and may originate directly from a product or from an information store containing information about installed products. The management software facilitates mining this information, parsing the information through a manifest of the triggers, and selecting functions to determine if a management operation should be executed, and if so, which management operation. Generally, the management software executes the selected management operation.

Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Abstract: This invention provides an extensible method for performing management operations on known and unknown targets. The extensible method is implemented on a fully extensible system where management software and triggers that cause these management operations to be run are easily extended in the field. The triggers may include information indicating a change in inventory, product state, or an event, and may originate directly from a product or from an information store containing information about installed products. The management software facilitates mining this information, parsing the information through a manifest of the triggers, and selecting functions to determine if a management operation should be executed, and if so, which management operation. Generally, the management software executes the selected management operation.

Abstract: The present invention relates to the use of a combination comprising (a) imatinib or a pharmaceutically acceptable salt thereof and midostaurin or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of gastrointestinal stromal tumors, e.g. imatinib-resistant gastro-intestinal stromal tumors.

Abstract: The automated software upgrade utility allows a customer, product supplier or software vendor to upgrade the operating system, firmware, applications and data files on any product regardless of the product type and characteristics. This upgrade process can be invoked from a remote location or via interaction directly with the target device.

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.

Abstract: An oncogene designated PAX8-PPAR&ggr;1 contains a PAX8 coding region fused to PPAR&ggr; coding region. Molecular characterization of PAX8-PPAR&ggr;1 molecules provides nucleotide and amino acid sequences useful for detection and treatment of certain tumors, particularly thyroid follicular carcinomas.

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.

Abstract: The invention is a method for genomic subtractive hybridization. Specific nucleic acid sequences are removed from a sample of nucleic acid sequences by specifically hybridizing the sequences to a complementary nucleic acid sequence bound to a target molecule such as biotin. The target molecule is then contacted with a binding partner such as avidin and separated from the sample of nucleic acid sequences. As the target is separated from the sample the hybridized nucleic acid sequences are also removed from the sample. The method preferably involves the removal of repetitive nucleic acid sequences from a nucleic acid sample to generate a library of probes that are substantially free of repetitive nucleic acid sequences.

Abstract: An oncogene designated PAX8-PPAR&ggr;1 contains a PAX8 coding region fused to PPAR&ggr; coding region. Molecular characterization of PAX8-PPAR&ggr;1 molecules provides nucleotide and amino acid sequences useful for detection and treatment of certain tumors, particularly thyroid follicular carcinomas.